Schrodinger Stock: Digging into The Business Model
Checking in with your stocks about once a year seems like the minimum cadence for a long-term tech investor. In reality, you’ll be checking in more often when dramatic stock price movements happen, or corporate events take place. Today, we’re going to check in on a company we haven’t written about in several years – Schrodinger Inc (SDGR).
The last time we wrote about the firm was in a piece titled A Computational Chemistry IPO From Schrodinger which looked at the S-1 filing document which accompanied their initial public offering (IPO) which took place in February 2020. Simply put, Schrodinger has developed a physics-based computational platform that uses artificial intelligence to help drug developers better predict which novel molecules will successfully pass the FDA drug approval gauntlet. The business model derives revenues from two main sources:
- Licensing software to customers – largely on-premise
- Capturing some downstream upside through royalties and milestone payments – large rewards if drugs are successful
Let’s start by looking at how overall revenue growth has been progressing.
Schrodinger’s Revenue Growth
In looking at Schrodinger’s latest revenue projections, steady growth across the business appears promising. The below information was current as of Q3-2021 earnings with 15% projected year-over-year growth for 2021 based on the lower end of their guidance.
Let’s see if we can better understand their business model by first examining the software business.
Schrodinger’s Software Business
Here’s what we said in our earlier piece:
In looking at the S-1 filing for Schrodinger, they largely install their software on location for their clients – on-premise – which means the revenue is recorded differently. In other words, it’s not a traditional Software-as-a–Service (SaaS) business model that’s easy to understand. Still, the principles of selling software remain the same regardless of how the revenue is being recognized.Credit: Nanalyze
The SaaS-related metrics provided by Schrodinger are found in their 10-K annual filing, but they’re named differently. Annual recurring revenue (ARR) is called annual contract value (ACV). That’s because Schrodinger largely sells licenses with one-year terms where cancelation terms are rather loose.
Our customers have no obligation to renew their product licenses or subscriptions for our software solutions after the license term expires, which is typically after one year, and many of our contracts may be terminated or reduced in scope either immediately or upon notice.Credit: Schrodinger
Because there is no recurring element to the transaction, Schrodinger reports these revenues as “point in time.”
The software point in time revenue nearly matches the percentage of revenues Schrodinger receives from selling on-premise software.
The next three categories – hosted software, software maintenance, and professional services – represent the “over time” revenues. Using the lower range of Schrodinger’s guidance, software revenues will barely clear double-digit growth this year with a 10% year-over-year increase. As for the “professional services” segment having declining growth, that seems a bit concerning. The company defines professional services as “training, technical support, installation, or assisting customers with modeling.” Those are the sorts of activities you engage in when onboarding new customers, so we’ll look forward to seeing the below chart updated for 2021:
Analysts seemed to pick up on the slowing software growth in the last earnings call when the CEO assured investors that “customers require significantly more licenses than what they have access to now” with the ideal penetration representing “somewhere in the range per company of around $30 million to $40 million.” He also talked about how the company expects to maintain its “long historic extremely high retention rate” by achieving “very, very high 90s” going forward.
Expectations and reality are often different, so gross retention rate (number of clients who don’t cancel) will be a key metric to watch going forward along with net retention rate (existing clients who spend more). The latter metric can be deduced from charts in the 10-K which show the number of clients who contribute $100,000 or more (153 in 2020) and the number of large clients which should always be growing.
Despite the slow growth, the software business seems healthy if they can keep growing all those numbers and maintain the low cancelation rate. Where the big upside seems to be is in the drug discovery segment.
Schrodinger’s Drug Discovery Revenues
- Downstream revenue streams aren’t “lumpy” as that creates volatility
- Present-day valuations aren’t richly priced in anticipation of future rewards
Regarding the first bullet point, Schrodinger mentioned this in their most recent earnings call stating, “revenue in this segment can be highly variable period-to-period as the decisions on program timelines are largely in the hands of our collaborators.” In fact, they lowered the upper range of the drug discovery revenue guidance from $32 million to $24 million for that very reason. However, for the past four years, drug discovery revenues have been consistently growing.
So, the question remains. Is the current valuation of Schrodinger giving too much weighting to future drug discovery revenues? We can answer that question by using our simple valuation ratio.
- Market capitalization / annualized revenues
1,870 / 119.6 = 16
Contrast that to Ginkgo Bioworks which currently has a ratio of 29 (that’s with pandemic and related revenues included). Sure, it’s apples to oranges, but the basic idea holds true. Even with drug discovery revenues removed, Schrodinger wouldn’t be excessively overvalued.
Schrodinger and Bristol Myers Squibb Company
The largest drug discovery partnership Schrodinger has is a multi-target collaboration with Bristol Myers Squibb (BMS). Last quarter, nearly 79% of drug discovery revenues were attributed to $4.4 million recognized from their collaboration with BMS.
Under the agreement, Schrodinger will spend – at their own cost – up to four years developing novel molecules for BMS to commercialize. In exchange, they received “an initial upfront fee payment of $55 million” and a promise of future riches – “up to $2.7 billion in total milestones across all potential targets.” Of course, that’s assuming BMS can successfully commercialize multiple molecules that Schrodinger develops, and that needs to happen to demonstrate the platform actually works as advertised. The icing on the cake? A tiered percentage royalty on annual global net sales for Schrodinger if BMS hits pay dirt with a successful blockbuster.
Schrodinger’s Recent Acquisition
The reason Schrodinger came across our radar again was news of their recent acquisition. On January 14, 2022, they acquired XTAL BioStructures for $6 million in cash in order to offer customers “access to protein structures that have been computationally validated and are ready for structure-based virtual screening and lead optimization.” Our recent article on Gandeeva Therapeutics and Cryogenic Electron Microscopy was well-timed because in that piece we learned about how structural biology works.
One tool used to examine proteins in great detail is x-ray crystallography, something XTAL specializes in. Schrodinger will use this tool to “scale up production of high-resolution structures” which serve as starting points for their computational platform. Providing more detailed input will certainly result in more accurate outputs.
Buying Schrodinger Stock
We’re presently long Schrodinger with a position that’s -40% below our cost basis with capital still remaining to allocate. In other words, there’s no reason we shouldn’t be adding shares right now, except that we’d rather wait until the year-end results come out.
Given the high expectations Wall Street analysts set for companies these days, sometimes a generally positive year-end will coincide with shares taking a big fat dump. Our plan is to be prepared in advance so that we might add shares if an opportunity arises early next month (year-end results are expected to be announced around March 2nd).
Schrodinger’s basic metrics appeared healthy up until last year, so next month’s updated numbers should be given a quick checkup. The company doesn’t seem to be overly valuing the promise of future revenues coming from the drug discovery business, and that’s great because the software business isn’t growing very fast. If no red flags are raised during the year-end results, we may add some more SDGR stock to our portfolio. If we do, Nanalyze Premium subscribers will be sent an alert.
Tech investing is extremely risky. Minimize your risk with our stock research, investment tools, and portfolios, and find out which tech stocks you should avoid. Become a Nanalyze Premium member and find out today!